[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-quality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-quality":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,89,0,25,[9,51,77,102,134,159,194,218,246,274,306,331,359,389,412,439,469,497,524,547,573,603,630,685,710],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100651954","effect-of-eye-mask-use-on-sleep-quality-and-delirium-after-cabg-surgery-100651954",false,"NCT07768020","Effect of Eye Mask Use on Sleep Quality and Delirium After CABG Surgery","The Effect of Eye Mask Use on Sleep Quality and Delirium Levels in Patients Following Coronary Artery Bypass Graft Surgery","EYE-CABG","Inclusion Criteria:\n\n* Aged 18 years or older\n* Scheduled to undergo elective coronary artery bypass graft surgery\n* Conscious, cooperative, and oriented\n* No diagnosed cognitive impairment that would prevent informed consent or completion of the study assessments\n* Able to communicate in Turkish\n* Baseline Nursing Delirium Screening Scale (Nu-DESC) score below 2\n* Able and willing to use an eye mask\n* Voluntarily agreed to participate and provided written informed consen\n\nExclusion Criteria:\n\n* Diagnosed sleep disorder\n* Regular use of sleep medication\n* Habitual use of an eye mask during sleep\n* Severe visual impairment or an ocular, facial, or skin condition preventing the safe use of an eye mask\n* Severe communication impairment preventing completion of the data collection instruments\n* Undergoing emergency coronary artery bypass graft surgery","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Coronary artery bypass graft (CABG) surgery is an effective treatment for coronary artery disease; however, sleep disturbances and delirium are common during the postoperative period and may adversely affect recovery. Environmental factors, particularly light exposure, can disrupt the sleep-wake cycle and contribute to poor sleep quality. Eye masks offer a simple, safe, and non-pharmacological method of reducing light exposure and supporting sleep. This study aims to determine the effect of eye mask use on sleep quality and delirium levels in patients following CABG surgery.",[28,29,30],"Coronary Artery Disease","Sleep Quality","Postoperative Delirium (POD)",[32,33,29,34,35,36,37],"Coronary Artery Bypass Grafting","Eye Mask","Postoperative Delirium","Cardiac Surgery","Non-Pharmacological Intervention","Postoperative Nursing Care","NOT_YET_RECRUITING","2026-08-11",{"date":41,"type":42},"2026-08-17","ACTUAL",{"date":44,"type":22},"2026-09-15",{"date":46,"type":22},"2026-12-30",{"name":48,"class":49},"Munzur University","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":50},"100650175","this-is-a-randomized-open-label-4-arm-pilot-study-designed-to-evaluate-the-efficacy-and-tolerability-of-four-qualia-sleep-formulations-formulas-a-b-c-and-d-in-healthy-adults-aged-18-years-and-older-who-report-poor-sleep-quality-the-investigational-products-are-encapsulated-dietary-supplement-100650175","NCT07744971","Comparison of Four Qualia Sleep Formulations on Sleep Quality : An Open-label 4-arm Pilot Study","Inclusion criteria:\n\n* Healthy female and male adults aged 18 years and older with poor sleep quality.\n* A raw score ≥25 on the PROMIS Sleep Disturbance - Short Form questionnaire (preference given to participants with a higher score).\n* Can read and write English.\n* Provide voluntary, written, informed consent to participate in the study.\n* Agree to provide a valid cell phone number and are willing to receive communications through text.\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.\n* Willing to complete questionnaires, records, and diaries associated with the study.\n\nExclusion criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.\n* Known food intolerances\u002Fallergy to any ingredients in the product.\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer.\n* Having had a significant cardiovascular event in the past 6 months.\n* Taking any of the following medications, or on immunosuppressive therapy:\n* Psychiatric or neurological medications - including antidepressants (e.g., MAO inhibitors, SSRIs) and anxiolytics\n* Sleep medications - sedatives, hypnotics, benzodiazepines, dual orexin receptor antagonists, melatonin receptor agonists\n* Individuals who were deemed incompatible with the test protocol.\n* Adults lacking capacity to consent.\n* Unable to read and understand English.",true,{"count":21,"type":22},[25],"This is a randomized, open-label, 4-arm pilot study designed to evaluate the efficacy and tolerability of four Qualia Sleep formulations (Formulas A, B, C, and D) in healthy adults aged 18 years and older who report poor sleep quality. The investigational products are encapsulated dietary supplements intended to support sleep quality and satisfaction. Approximately 100 participants will be allocated to one of four arms (n≈25 per arm) and will take 2 capsules of their assigned Qualia Sleep formula once daily for 28 consecutive days, administered 30-60 minutes before bedtime. The primary objective is to assess changes in sleep quality and satisfaction from baseline to Day 28 using the PROMIS Sleep Disturbance - Short Form 8b, with secondary outcomes including sleep-related impairment, pre-sleep arousal, and overall safety and tolerability. All study data, including self-reported sleep and safety questionnaires, will be collected electronically via secure links; there are no in-person visits or clinic-based assessments.",[29],[63,64,65,66],"sleep quality","pre-sleep arousal","sleep-related daytime impairment","dietary supplement","2026-08-10",{"date":69,"type":42},"2026-08-12",{"date":71,"type":22},"2026-08-28",{"date":73,"type":22},"2026-10-31",{"name":75,"class":76},"Qualia Life Sciences","INDUSTRY",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":50},"100649273","acupoint-stimulation-and-exercise-for-taiwanese-pre-frail-older-adults-100649273","NCT07732530","Acupoint Stimulation and Exercise for Taiwanese Pre-frail Older Adults","Exploring the Associations Among Frailty, Daily Physical Activity, Sleep, and Traditional Chinese Medicine Constitution in Taiwanese Older Adults, and Evaluating the Effects of Acupoint Stimulation Interventions","Inclusion Criteria:\n\n1. Individuals who are capable of undergoing frailty assessments.\n2. Individuals who possess effective communication skills.\n3. Aged 50 years or older.\n4. Willing to provide written informed consent, keep a 7-day sleep diary, and complete related questionnaires.\n5. Identified as pre-frail (frailty score of 1-2 points) according to the frailty phenotype criteria for the clinical trial phase.\n\nExclusion Criteria:\n\n1\\. Individuals who are unwilling or unable to wear an actigraph (wrist monitor) or undergo physical measurements.","50 Years",{"count":86,"type":22},30,[25],"This study aims to explore the relationships between frailty, daily physical activity, sleep quality, and Traditional Chinese Medicine (TCM) constitutions among older adults in Taiwan. In the trial phase, a randomized controlled trial will be conducted specifically for pre-frail older adults. Participants will be randomly assigned to either the exercise training group (Vivifrail program) or the integrated group combining exercise with daytime and sleep-improving acupoint stimulation. The study evaluates the combined efficacy of these non-invasive interventions on reducing frailty severity, improving sleep, and enhancing daily physical functions.",[90,29,91],"Frailty","Aging","RECRUITING","2026-08-04",{"date":95,"type":42},"2026-08-07",{"date":97,"type":42},"2025-06-03",{"date":99,"type":22},"2027-12-31",{"name":101,"class":49},"Tainan Hospital, Ministry of Health and Welfare",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":57,"sex":18,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":50},"100629370","social-media-diet-and-psychological-outcomes-in-university-students-100629370","NCT07473791","Social Media Diet and Psychological Outcomes in University Students","The Effect of a Social Media Diet on Loneliness, Fear of Missing Out, and Sleep Quality Among University Students: A Randomized Controlled Trial","The Effect of","Inclusion Criteria:\n\n* Being between the ages of 18-25.\n* Being a student at Gumushane University Kelkit Sema Dogan Vocational School of Health Services.\n* Having a daily social media usage time of at least 2 hours (verified by smartphone screen time settings).\n* Owning a smartphone (Android or iOS).\n* Volunteering to participate in the study and providing written informed consent.\n\nExclusion Criteria:\n\n* Having a diagnosed clinical sleep disorder (e.g., sleep apnea, chronic insomnia) or using prescribed sleep medication.\n* Having a diagnosed psychiatric disorder that may interfere with social media use or perception of loneliness.\n* Use of other digital detox or time-management applications during the study period.\n* Being unable to provide weekly screen time screenshots.\n* Planning to change smartphone device during the 4-week intervention period.","17 Years","25 Years",{"count":113,"type":22},70,[25],"This study aims to examine the effect of a social media diet intervention on loneliness, fear of missing out (FoMO), and sleep quality among university students. Excessive social media use has been associated with several negative psychological outcomes, including increased loneliness, heightened FoMO, and poor sleep quality.\n\nIn this randomized controlled trial, university students will be randomly assigned to either an experimental group or a control group. Participants in the experimental group will follow a social media diet intervention that involves limiting daily social media use for a specified period, while participants in the control group will continue their usual social media use without restrictions.\n\nLoneliness, FoMO, and sleep quality will be measured at baseline and after the intervention using validated scales. The findings of this study are expected to provide evidence on whether reducing social media use can improve psychological well-being and sleep quality among university students.",[117,118,29],"Loneliness","Fear of Missing Out",[120,121,122,123,124],"Social Media Diet","Digital Detox","University Students","Behavioral Intervention","Randomized Controlled Trial","2026-07-31",{"date":127,"type":42},"2026-08-03",{"date":129,"type":42},"2026-03-10",{"date":131,"type":22},"2026-08",{"name":133,"class":49},"Gümüşhane Universıty",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":50},"100618796","phase-3-sleep-quality-and-the-efficacy-of-a-multimodal-sleep-pathway-in-hospitalized-orthopedic-trauma-patients-100618796","NCT07336277","Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients","Inclusion Criteria:\n\n* Hospitalized with an isolated lower extremity orthopedic injury requiring surgical intervention.\n* Expected hospital stay of at least 3 days.\n* No known pre-existing sleep disorders.\n* No current use of sleep aids, such as zolpidem or melatonin, before hospitalization\n\nExclusion Criteria:\n\n* Participants with a history of chronic opioid use prior to hospitalization.\n* Pre-existing diagnosed sleep disorders (e.g., obstructive sleep apnea, insomnia).\n* Contraindications to zolpidem or melatonin use (e.g., allergies, interactions with other medications).\n* Cognitive impairment or inability to comply with study procedures.\n* Severe traumatic brain injury or other neurological conditions that may affect sleep or pain perception.\n* Participants receiving mechanical ventilation or sedatives that significantly affect sleep architecture.","65 Years",{"count":86,"type":22},[143],"PHASE3","The goal of this study is to determine whether a multimodal sleep pathway can enhance sleep quality in hospitalized patients with orthopedic trauma. It will also evaluate the effect of this pathway on opioid use and pain perception during recovery.\n\nThe main study questions are:\n\n* Does the multimodal sleep pathway improve sleep quality and duration?\n* Does the pathway reduce the amount of opioids patients use during hospitalization?\n* Does improved sleep reduce pain interference with daily activities?\n\nResearchers will compare the multimodal sleep pathway to standard postoperative care to see if the pathway helps patients sleep better and rely less on opioids.\n\nParticipants will:\n\n* Receive either the multimodal sleep pathway (zolpidem, melatonin, and sleep hygiene education) or standard care\n* Wear a wrist-worn actigraphy device to track sleep during their hospital stay\n* Complete daily questionnaires about sleep quality and pain",[146,29],"Orthopedic Trauma",[148,29,149],"Multimodal Sleep Pathway","Opioid consumption","2026-07-29",{"date":152,"type":42},"2026-07-30",{"date":154,"type":42},"2026-06-02",{"date":156,"type":22},"2027-07",{"name":158,"class":49},"Emory University",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":171,"conditions":172,"keywords":179,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100609792","early-phase-1-kava-aging-and-mobility-study-100609792","NCT07219186","Kava Aging and Mobility Study","Impacts of AB-free Kava on Mitigating Mobility Loss With Aging: A Pilot Study","Inclusion Criteria:\n\n* Age \\> 70 years\n* 8 ≤ Insomnia severity index (ISI) ≤21\n* 4m walking speed \\\u003C1 m\u002Fsec and \\>0.44 m\u002Fsec\n* Mild to moderate physical impairment (Short Physical Performance Battery score \\\u003C 10)\n* Sedentary lifestyle (\\\u003C 150 min per week of moderate intensity physical activity) verified by CHAMPS questionnaire\n* Willingness and ability to give informed consent\n* Willingness to be randomized to the intervention groups\n* Availability for participation through duration of study Exclusion Criteria (General)\n* Failure to provide informed consent\n* History or clinical manifestation of diabetes, cholelithiasis, liver or renal disease, cancer, or progressive, degenerative neurologic disease (e.g., Parkinson's Disease, multiple sclerosis, ALS)\n* Abnormal laboratory markers (e.g., renal or liver abnormalities, elevated potassium levels, or hemoglobin and hematocrit below the lower limit of normal)\n* Residence in a Skilled Nursing Facility (SNF); residence in an Assisted Living Facility (ALF) or independent housing is allowed\n* Self-reported inability to walk one block\n* Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental Status Exam score \\\u003C 24\n* Severe rheumatologic or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease)\n* Terminal illness with life expectancy less than 12 months, as determined by a physician\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Severe pulmonary disease, pneumonitis or interstitial lung disease\n* Other significant co-morbid disease (e.g. renal failure on hemodialysis) or severe psychiatric disorder (e.g. bipolar, schizophrenia)\n* Current use of antidepressant medications, antipsychotic agents, monoamine oxidase inhibitors, anticholinesterase inhibitors (i.e., Aricept)\n* Refuses to reduce alcohol use to 3 or fewer alcoholic drinks per week during the study\n* Planning to permanently leave the area in the next year\n* Blood pressure readings \\>180\u002F100 at screening\n* Participating in another clinical trial or has received an investigational product within 30 days prior to screening\u002Fenrollment.\n\nExclusion Criteria (AB-free kava-related)\n\n* Regular use of any medications that contain acetaminophen\n* Current use of any forms of kava and not willing to stop for a 2-week washout period - dietary supplements or beverages\n* Current use of antidepressant medications and antipsychotic agents (including monoamine oxidase inhibitors), or anticholinesterase inhibitors (i.e., Aricept)\n* Diagnosed with liver dysfunction or with previous liver diseases during the past five years\n* Levels of ALT, AST, ALP or total bilirubin over 3xlimit of normal (ULN) range at prescreen\n\nTemporary Exclusion Criteria\n\n* Acute infection (urinary, respiratory, other) or hospitalization within 1 month\n* Myocardial infarction, CABG, or valve replacement within past 6 months\n* Pulmonary embolism or deep venous thrombosis within past 6 months\n* Stroke, hip fracture, hip or knee replacement, or spinal surgery within past 4 months\n* Receiving physical therapy for gait, balance, or other lower extremity training","70 Years",{"count":168,"type":22},40,[170],"EARLY_PHASE1","The goal of this clinical trial is to learn if AB-free kava works to improve mobility and physical function in older adults with sleep difficulties. It will also learn about the safety of AB-free kava. The main questions it aims to answer are:\n\n* Does AB-free kava improve physical function and\u002For mobility?\n* Does AB-free kava effect sleep, stress, or cellular signaling? Researchers will compare AB-free kava to a placebo (a look-alike substance that contains no drug) to see if AB-free kava works to improve mobility and physical functioning.",[173,29,174,175,176,177,178],"Old Adults","Kava","Mobility Impairment","Physical Activity and Stress","Physical Impairment","Sedentary Lifestyle in Patients Over 70",[180,181,182,183],"AB-free Kava","Old adults","Sleep Difficulties","Mobility Limitations","2026-07-21",{"date":186,"type":42},"2026-07-23",{"date":188,"type":22},"2027-01",{"date":190,"type":22},"2027-05",{"name":192,"class":49},"University of Florida",2,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":140,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100648412","a-clinical-trial-to-evaluate-the-effects-of-the-edgeease-pmam-system-on-mood-mental-clarity-sleep-quality-and-digestive-wellbeing-100648412","NCT07721506","A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing","Inclusion Criteria:\n\n* Male and female adults aged 18 to 65 years.\n* Self-reports difficulty falling asleep, staying asleep, or having poor sleep quality overall, in the last 4 weeks.\n* Self-reports seeking support in at least one of the following domains: Difficulty switching off, perceived stress load, mental overload, next-day mental fatigue, reduced mental clarity or reduced cognitive readiness.\n* Generally healthy.\n* Willing and able to take the PM product (one serving mixed in water) in the evening and the AM product (two capsules with food) in the morning daily for 12 weeks.\n* Willing to maintain current diet, exercise, caffeine, alcohol, and sleep routines for the duration of the study.\n* Willing to wear a Fitbit continuously during the trial, and for 7 days prior to starting the test product.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any ingredient in the test product.\n* Currently pregnant, breastfeeding, or trying to conceive, or will be during the study period.\n* Currently undergoing treatment for cancer, or have had a serious illness requiring hospitalization in the last 3 months.\n* Diagnosed severe psychiatric disorder (e.g., bipolar disorder, schizophrenia, major depressive disorder requiring active treatment adjustment) that, in the judgment of the Investigator, would compromise participation or interpretation of results.\n* Diagnosed inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or other significant gastrointestinal condition requiring active management.\n* Current use of prescription antidepressants\u002Fanxiolytics, or other prescription neurologically-active medications that have been initiated or had a dose change within the past 90 days.\n* Current use of prescription sleep medications.\n* Regular use (i.e. more than once per week) of melatonin, sedating antihistamines, CBD\u002FTHC used for sleep, valerian, ashwagandha, or other sleep-targeted supplements.\n* Initiation of a new dietary supplement targeted at sleep, mood, cognition, or digestion within the 30 days prior to enrollment, or planning to start such a supplement during the study.\n* Heavy drinkers, defined as more than 8 alcoholic drinks per week for women and more than 15 alcoholic drinks per week for men.\n* Currently taking thyroid medication.\n* Currently testing, or plan to in the next 12 weeks, a product for another research study.",{"count":201,"type":22},35,[25],"This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy adults aged 18-65 years over 12 weeks of daily use.\n\nParticipants will take the Edge+Ease PM product (one serving of powder mixed in approximately 150-250 mL water) in the evening approximately 60-90 minutes before bedtime, and the Edge+Ease AM product (two capsules) in the morning with food. All study activities are conducted remotely via the Citruslabs platform. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will wear a Fitbit continuously beginning 7 days before product use through the end of the 12-week intervention period to provide objective sleep data.",[29,205,206,207,208,209,210],"Mood","Mental Clarity","Brain Fog","Digestive Comfort","Focus","Evening Wind-Down","2026-07-18",{"date":186,"type":42},{"date":131,"type":22},{"date":215,"type":22},"2026-12",{"name":217,"class":76},"Edge+Ease",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":57,"sex":225,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":50},"100647481","magnesium-supplement-for-sleep-quality-in-women-with-poor-sleep-100647481","NCT07708857","Magnesium Supplement for Sleep Quality in Women With Poor Sleep","Effects of Magnesium Breakthrough on Sleep Quality and Mood in Women With Poor Sleep: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial","Inclusion Criteria:\n\n* Women aged 35-60 U.S.-based, fluent in English Insomnia Severity Index score ≥8 (poor\u002Fsubclinical insomnia) and \\\u003C22 (excluding severe clinical insomnia) No formal sleep disorder diagnosis Consistent bedtime routine (+\u002F-1 hr) Not currently using prescription sleep medications Owns a compatible smartphone (iOS or Android) capable of running the Oura Ring app and study digital platform Willing to wear the Oura Ring throughout the entire study period Nonsmoker Able to provide informed consent and complete all activities\n\nExclusion Criteria:\n\n* Diagnosed sleep disorder Current diagnosis of depression or anxiety disorder Current use of bisphosphonates (e.g., alendronate, risedronate) Shift worker or highly irregular sleep schedule Pregnancy or breastfeeding Known sensitivity to product ingredients Current use of supplements containing more than 25 mg of elemental magnesium Coffee intake greater than 3 cups per day (or equivalent caffeine from other beverages) External or lifestyle factors that may affect sleep patterns (e.g., infant\u002Fchild regularly wakening, excessive noise, snoring partner, pain condition, variable work\u002Fstudy schedule, or mid-to-late afternoon\u002Fevening caffeine intake) BMI ≥32 kg\u002Fm² Current diagnosis of chronic kidney disease or renal impairment, or current use of prescription diuretics Use of melatonin \\>1 mg within 14 days of baseline Recent major life event or acute psychosocial stressor within 30 days of baseline (e.g., bereavement, job loss, separation) that may independently disrupt sleep Participation in other clinical trials in past 30 days\n\nCriteria:\" as headers within a single text field)?","FEMALE","35 Years","60 Years",{"count":229,"type":22},50,[25],"This study will test whether a magnesium supplement (Magnesium Breakthrough) improves sleep quality and mood in women ages 35 to 60 who have poor sleep but no diagnosed sleep disorder. Participants will take the magnesium supplement for two weeks and a matched placebo for two weeks, in random order, separated by a one-week washout period. Neither participants nor study staff will know which product is being taken during each period.\n\nThroughout the study, participants will wear an Oura Ring to track sleep patterns and will complete short daily and biweekly questionnaires about their sleep, mood, stress, and energy levels. The main measure of interest is change in sleep quality, assessed using a validated sleep questionnaire (the Pittsburgh Sleep Quality Index). The study will also look at effects on mood, stress, and objective sleep measures from the Oura Ring.\n\nAll study activities - screening, consent, and data collection - are conducted remotely, so participants can take part from anywhere in the United States.",[29],[234,63,235,236],"magnesium","crossover trial","middle-aged women","2026-07-16",{"date":239,"type":42},"2026-07-20",{"date":241,"type":22},"2026-09",{"date":243,"type":22},"2026-11",{"name":245,"class":49},"Jacksonville University",{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":57,"sex":18,"minAge":140,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":261,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":50},"100647664","mindfulness-for-lonely-older-adults-with-emigrant-children-100647664","NCT07711860","Mindfulness for Lonely Older Adults With Emigrant Children","Feasibility and Acceptability of Implementation of Mindfulness-Based Intervention for Community-Dwelling Older Adults With Emigrant Children Suffering From Loneliness: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Chinese adults aged 65 to 75 years,\n2. able to communicate and understand Cantonese (class will be held in Cantonese),\n3. OAs with or without emigrant children,\n4. feeling of loneliness (3-item UCLA ≥6) \\[25\\], and\n5. living in public housing, reliant on pension, savings, or living in subvented housing.\n\nExclusion Criteria:\n\n1. Acute or severe physical symptoms such as impaired mobility, COPD or respiratory failure, uncontrolled epilepsy, and severe chronic pain syndrome,\n2. Abbreviated Mental Test (AMT)\\\u003C 6 \\[26\\],\n3. met DSM-V TR criteria for treated or untreated major depressive disorder, bipolar disorder, cyclothymic disorder and\u002For on regular medication treatment,\n4. have significant suicidal risk, and\n5. previous experience in instructor-led mindfulness training within the half year prior to the commencement of the study.","75 Years",{"count":255,"type":22},90,[25],"This study is to examine the feasibility of a proposed mindfulness-based intervention (MBI) and study methodology for future main study.",[117,29,259,260],"Quality of Life","Stress",[262,263,264],"Mindfulness-based intervention","loneliness","older adults with emigrant children","2026-07-14",{"date":267,"type":42},"2026-07-17",{"date":269,"type":22},"2026-10-01",{"date":271,"type":22},"2028-03-31",{"name":273,"class":49},"Hong Kong Metropolitan University",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":285,"conditions":286,"keywords":290,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":50},"100645802","sleep-chronotype-and-prosocial-allocation-decisions-100645802","NCT07697092","Sleep, Chronotype, and Prosocial Allocation Decisions","Associations Between Sleep Quality, Circadian Timing, and Prosocial Allocation Decisions in Adults","SCPAD","Inclusion Criteria:\n\n* Aged 18 years or above.\n* Able to provide informed consent.\n* Able to understand English or Chinese study materials.\n* Able to complete computer-based behavioural tasks and self-report questionnaires.\n* Willing to complete a 7-day sleep diary.\n\nExclusion Criteria:\n\n* Aged under 18 years.\n* Unable to provide informed consent.\n* Unable to complete study materials in English or Chinese.\n* Prior participation in the same study.\n* Self-reported condition or circumstance that would make participation in a brief computer-based decision-making task or sleep-related questionnaires inappropriate or distressing.",{"count":283,"type":22},128,"OBSERVATIONAL","This observational behavioural study examines whether individual differences in sleep quality, sleep timing, and chronotype are associated with prosocial allocation decisions in adults. Participants will complete self-report sleep and circadian questionnaires, including the Pittsburgh Sleep Quality Index and the Munich Chronotype Questionnaire, a 7-day sleep diary, and a brief computer-based Dictator Game allocation task.\n\nThe study does not involve sleep deprivation, sleep restriction, treatment, clinical diagnosis, medication, or medical devices. Participants will not be asked to change their sleep schedule. The Dictator Game decisions are hypothetical and do not affect participants' compensation. The study is intended to describe associations between naturally occurring sleep-related individual differences and behavioural allocation choices, not to diagnose or treat sleep or mental health conditions.",[29,287,288,289],"Chronotype","Prosocial Decision-Making","Circadian Timing",[29,287,289,291,292,293,294,295,288,296],"Pittsburgh Sleep Quality Index","Munich Chronotype Questionnaire","Sleep Diary","Dictator Game","Prosocial Behavior","Allocation Decisions","2026-07-06",{"date":299,"type":42},"2026-07-13",{"date":301,"type":22},"2026-07",{"date":303,"type":22},"2028-06",{"name":305,"class":49},"The Hong Kong Polytechnic University",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":140,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":315,"conditions":316,"keywords":319,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":193},"100646386","digital-and-plasma-biomarkers-in-delirium-100646386","NCT07694206","Digital and Plasma Biomarkers in Delirium","Delirium Evaluation With Longitudinal Tau Assessment","DELTA","Inclusion Criteria:\n\n* Admitted to the intensive care unit\n* Able to consent or have a legally authorized representative consent on their behalf\n* English speaker\n* Expected ICU stay of 48 hours or more\n\nExclusion Criteria:\n\n* Advanced dementia\n* End stage liver disease\n* Renal replacement therapy\n* Structural brain injury, including but not limited to traumatic brain injury, cerebrovascular accident and intracranial hemorrhage,",{"count":21,"type":22},"The goal of this observational study is to learn if there are potential digital and plasma-based biomarkers that could help detect, predict, and prognosticate delirium in older adult patients who are admitted to the intensive care unit (ICU). The main question DELTA aims to answer is:\n\nCan digital biometrics predict and detect delirium in older adult ICU patients? Do biomarkers of neurodegeneration fluctuate in ICU patients in such a way that delrium could potentially be predicted?\n\nParticipants admitted o the ICU will wear a digital device to collect biometric data and will have serial plasma samples collected during ICU admission and patients will be also assessed for delirium daily by study staff.",[317,318,29],"Critical Illness","Delirium in the Intensive Care Unit",[320,321,322],"Sleep in the ICU","Delirium in the ICU","Delirium biomarkers","2026-07-02",{"date":325,"type":42},"2026-07-09",{"date":327,"type":42},"2026-05-28",{"date":99,"type":22},{"name":330,"class":49},"Scripps Health",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":57,"sex":225,"minAge":338,"maxAge":140,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":50},"100645147","effect-of-zenrest-lotus-seed--rice-germ-extract-blend-on-sleep-quality-in-menopausal-women-100645147","NCT07678359","Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women","A Randomized, Double-Blind, Placebo-Controlled, 6-Week Pilot Study to Evaluate the Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women","Inclusion Criteria:\n\n* Female, aged 40-65 years at time of enrollment\n* Confirmed menopausal status: (a) natural menopause (≥12 consecutive months of amenorrhea without other clinical cause), or (b) surgical menopause (bilateral oophorectomy with documented date of procedure)\n* Positive onboarding sleep screener: rates sleep quality as \"Fairly Bad\" or \"Very Bad\" AND reports sleep difficulty at least once per week in the prior month\n* PSQI global score \\>5 at T0 baseline assessment (formal eligibility gate)\n* Owns and actively uses an Oura Ring Generation 4 at time of enrollment\n* Demonstrates ≥80% Oura Ring wear compliance in the 30 days prior to enrollment, confirmed via Alethios platform sync at onboarding\n* Willing to wear Oura Ring Generation 4 continuously for 42 nights throughout the study period\n* Willing to maintain stable diet, sleep habits, medications, and supplement use throughout the 42-day study period\n* No planned major disruptions to sleep schedule, shift work, or travel across ≥3 time zones during the study period\n* Access to a smartphone or computer to complete eConsent and digital questionnaires\n* Able to provide informed consent via the Alethios eConsent platform\n\nExclusion Criteria:\n\n* Current use of prescription sleep medications (benzodiazepines, non-benzodiazepine hypnotics, doxepin, suvorexant) within 30 days of enrollment\n* Current use of melatonin supplements at doses \\>1 mg\u002Fday within 14 days of enrollment\n* Diagnosis of a clinically significant sleep disorder requiring treatment (obstructive sleep apnea unless adequately treated and stable, restless legs syndrome, narcolepsy)\n* Diagnosis of a major psychiatric disorder currently requiring pharmacological treatment\n* Current use of hormone replacement therapy initiated within 90 days of enrollment, or any planned changes to HRT during the study (stable long-term HRT is acceptable)\n* Regular use of GABAergic, serotonergic, or sedating supplements (valerian, passionflower, ashwagandha, kava) within 14 days of enrollment\n* Shift work or schedule regularly requiring sleep between 06:00 and 22:00\n* Planned travel across 3 or more time zones during the 42-day study period\n* Known allergy to lotus, rice, or related botanicals\n* Active cardiovascular, hepatic, renal, or neurological condition that in the PI's judgment would affect sleep or participant safety\n* Participation in another interventional study within 30 days of enrollment\n* In the opinion of the PI, any condition compromising participant safety or data integrity","40 Years",{"count":340,"type":22},60,[25],"The goal of this clinical trial is to learn if ZenRest™ (Lotus Seed \\& Rice Germ Extract Blend) can help improve sleep quality in menopausal women aged 40-65 with mild-to-moderate sleep complaints.\n\nThe main questions it aims to answer are:\n\n* Does taking ZenRest™ daily improve subjective, participant-reported sleep quality compared to a placebo?\n* Does ZenRest™ improve objective sleep metrics, specifically sleep efficiency, when monitored via an Oura Ring wearable device?\n* Does the extract improve secondary sleep and lifestyle factors, such as insomnia severity, daytime sleepiness, and vitality? Researchers will compare ZenRest™ to a placebo (a look-alike capsule that contains no active ingredients) to see if the botanical blend has a measurable effect on sleep quality.",[29,344],"Menopause",[346,347,348,349,350,344,29],"ZenRest","Lotus Seed Extract","Rice Germ Extract","Spermidine","Neferine","2026-06-25",{"date":353,"type":42},"2026-07-01",{"date":301,"type":22},{"date":356,"type":22},"2026-10",{"name":358,"class":76},"Nutraland USA, Inc.",{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":57,"sex":225,"minAge":366,"maxAge":227,"enrollmentInfo":367,"targetDuration":369,"studyType":284,"phases":4,"briefSummary":370,"conditions":371,"keywords":377,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100643860","multidimensional-determinants-of-functional-health-in-women-aged-45-60-100643860","NCT07667699","Multidimensional Determinants of Functional Health In Women Aged 45-60","Multidimensional Determinants and Structural Foundations of Functional Health In Women Aged 45-60: The Role of Muscle and Bone Health","Inclusion Criteria are:\n\n* Women aged 45 to 60 years\n* Ability to read and complete study questionnaires\n* Provision of written informed consent\n* Ability to complete physical performance assessments\n\nExclusion Criteria are:\n\n* Acute systemic illness\n* Active malignancy\n* Severe neurological or orthopedic impairment limiting physical performance assessment\n* Cognitive impairment precluding informed consent or questionnaire completion","45 Years",{"count":368,"type":22},200,"1 Day","The goal of this observational study is to learn about the multidimensional determinants of functional health in women aged 45 to 60 years. The study will focus on the role of muscle strength, bone mineral density, body composition, physical activity, sleep quality, depressive symptoms, and menopause-related symptoms in functional health.\n\nThe main questions it aims to answer are:\n\n1. Does muscle strength contribute to functional health in women aged 45 to 60 years?\n2. Does bone mineral density contribute to functional health in women aged 45 to 60 years?\n3. How are physical activity, sleep quality, depressive symptoms, body composition, and menopause-related quality of life associated with functional health?\n\nParticipants will:\n\n* Undergo handgrip strength measurement\n* Perform a 30-second chair stand test\n* Undergo bone mineral density and body composition assessment\n* Complete questionnaires about physical activity, sleep quality, depressive symptoms, menopausal symptoms, and quality of life\n* Provide demographic and clinical information",[372,373,374,375,376,29,259],"Healthy","Perimenopausal Depression","Menopausal Complaints","Bone Mineral Density","Sarcopenia",[344,378,379,376,29,380],"Perimenopause","Bone mineral density","Quality of life","2026-06-19",{"date":351,"type":42},{"date":384,"type":22},"2026-06-15",{"date":386,"type":22},"2026-12-31",{"name":388,"class":49},"Kartal City Hospital",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":50},"100642065","bruxism-therapy-of-facial-pain-100642065","NCT07611643","Bruxism Therapy of Facial Pain","Effect of Therapy for Myofascial Facial Pain on Bruxism\u002FNocturnal Clenching. Prospective, Non-profit Interventional Study Using a Device.","BRUXI","Inclusion Criteria:\n\n* Adult subjects aged ≥ 18 years\n* Subjects willing to provide written informed consent\n* Patients with temporomandibular disorders who have an indication for treatment with a gnathological occlusal splint\n\nExclusion Criteria:\n\n* Patients who change their pharmacological regimen during the monitoring period, as drug therapy may affect facial pain and\u002For muscle activity.",{"count":398,"type":22},42,[25],"This prospective, non-profit study aims to better understand how occlusal splints (gnathological splints) affect daytime and nighttime bruxism (teeth grinding) and clenching in adults with chronic myofascial pain of the jaw muscles, a common form of temporomandibular disorder (TMD). Bruxism and clenching are repetitive or sustained jaw muscle activities that can contribute to jaw pain and dysfunction, and their accurate diagnosis requires instrumental assessment of muscle activity. In this study, muscle activity will be objectively measured using a portable device (dia-BRUXO®) worn for 24 hours, which records the electrical activity of the chewing muscles during both wakefulness and sleep. Adult patients with TMD who are prescribed a night-time occlusal splint will undergo three 24-hour recordings: before using the splint, two weeks after starting treatment, and two months later. During each recording, participants will also report their facial pain levels and awareness of clenching or grinding during the day. Their results will be compared with those of a matched control group without TMD. The main goal is to compare jaw muscle activity between patients and healthy individuals, while secondary goals include analyzing how long the muscles are active and how these patterns relate to symptoms. By combining objective measurements and patient-reported experiences, this study seeks to clarify how occlusal splints influence muscle activity and symptoms, helping clinicians improve diagnosis and treatment of bruxism and TMD.",[402,403,29],"Bruxism","Bruxism, Sleep-Related",{"date":405,"type":42},"2026-06-17",{"date":407,"type":42},"2026-01-12",{"date":409,"type":22},"2027-01-10",{"name":411,"class":49},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":50},"100642017","effect-of-asmr-and-white-noise-on-sleep-quality-in-patients-undergoing-elective-lower-extremity-surgery-100642017","NCT07651228","Effect of ASMR and White Noise on Sleep Quality in Patients Undergoing Elective Lower Extremity Surgery","Effect of ASMR and White Noise on Sleep Quality in Patients Undergoing Elective Lower Extremity Surgery: A Randomized Controlled Trial","SLEEP-ASMR","Inclusion Criteria:\n\n* Age 18 years and older\n* Undergoing elective lower extremity surgery\n* Conscious and able to communicate\n* No hearing impairment or hearing aid use\n* Numeric Rating Scale (NRS) pain score of 5 or lower\n* No use of medications affecting sleep\n* Willing to participate in the study\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Participation in another clinical study\n* Surgery due to trauma\n* Transfer to the intensive care unit during the postoperative period\n* Development of serious postoperative complications\n* Withdrawal from the study at any stage\n* Failure to comply with study procedures",{"count":255,"type":22},[25],"This randomized controlled trial aims to evaluate the effects of Autonomous Sensory Meridian Response (ASMR) and white noise on postoperative sleep quality in patients undergoing elective lower extremity surgery. Postoperative sleep disturbances are common after orthopedic surgery and may negatively affect pain perception, recovery, and overall patient outcomes. Participants will be randomly assigned to one of three groups: ASMR intervention, white noise intervention, or control group. Patients in the intervention groups will listen to standardized 30-minute audio recordings before sleep during the postoperative period, while the control group will receive routine care with headphones only. Sleep quality will be assessed using the Richards-Campbell Sleep Questionnaire (RCSQ). The study aims to determine which non-pharmacological intervention is more effective in improving postoperative sleep quality.",[424,425,29],"Postoperative Sleep Disturbance","Orthopedic Surgery Patients",[427,428,29,429,430],"ASMR","White Noise","Orthopedic Surgery","Lower Extremity Surgery",{"date":432,"type":42},"2026-06-16",{"date":434,"type":22},"2026-09-05",{"date":436,"type":22},"2027-01-05",{"name":438,"class":49},"muzeyyen ataseven",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":57,"sex":225,"minAge":226,"maxAge":140,"enrollmentInfo":446,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":50},"100642790","temple-massager-system-study-in-women-ages-35-65-100642790","NCT07639658","Temple Massager System Study in Women Ages 35-65","Temple Massager System: Impact on Anxiety, Emotional Wellbeing, and Quality of Life in Women Aged 35-65","Inclusion Criteria:\n\n* Female, aged 35-65 years old, inclusive\n* Self-reported experience of daily stress, anxiety, tension headaches, facial tension, or TMJ-related discomfort\n* Headache frequency of 2 or more per week (self-reported)\n* If taking any prescription medication including SSRIs, anxiolytics, sleep medications, hormonal therapies, or blood pressure medications, must be on a stable dose for at least 4 weeks prior to study enrollment and throughout the course of the study\n* In good general health at the time of screening (Investigator discretion)\n* Able to read and understand English\n* Able to read, understand, and provide informed consent\n* Able to use a personal smartphone or tablet and access the study platform for daily data entry\n* Able to receive shipment of the study product at an address within the United States\n* Willing and able to use the Temple Massager System daily for 4 weeks\n\nExclusion Criteria:\n\n* No personal smartphone or tablet, no internet access, or unwilling to use the study platform\n* Known allergy or sensitivity to lavender oil, mango butter, shea butter, arnica, or St. John's Wort (Note: lavender sensitivity alone is not exclusionary; an aromatherapy sensitivity protocol applies)\n* Active skin infection or open wounds on the face or temple area\n* Diagnosed trigeminal neuralgia or other cranial nerve pathology\n* Diagnosed vascular issues affecting the head or face: temporal arteritis, aneurysm, or cerebrovascular malformations\n* Bleeding disorders: history of easy bruising or bleeding in the face\u002Fhead area, or current use of prescribed blood thinners (anticoagulants) such as Warfarin or Eliquis\n* Any surgery on the jaw, temples, or face within the last 6 months\n* Active inflammation: current redness, swelling, or extreme tenderness specifically over the temple arteries\n* Current use of prescription headache medications (triptans, topiramate, muscle relaxants, beta-blockers for migraine prophylaxis, or other prescription medications taken primarily for headache management)\n* Participants currently taking any prescribed medication for sleep or anxiety must be on a stable dose (no dose changes within the past 30 days) to be eligible; participants not on a stable dose are excluded\n* Current participation in another interventional study\n* Diagnosed Generalized Anxiety Disorder (GAD)\n* Currently pregnant, planning to become pregnant during the study period, or breastfeeding\n* Planned surgical procedure during the study period\n* Significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes\n* Unlikely for any reason to be able to comply with the study or considered unsuited for participation by the Principal Investigator",{"count":447,"type":22},48,"The goal of this observational study is to learn how the Temple Massager System affects stress, emotional wellbeing, sleep, and quality of life in women aged 35 to 65.\n\nThe Temple Massager System is a non-electric, drug-free hand-held device used for self-massage of the temple area. The system also includes a body lotion and an optional lavender aromatherapy. It is sold as a general wellness product.\n\nThe main questions this study aims to answer are:\n\nDoes daily use of the Temple Massager System lower self-reported stress and improve emotional wellbeing over 4 weeks? Does daily use improve self-reported sleep quality and overall quality of life?\n\nThis is a single-arm observational study. There is no placebo or comparison group. Researchers will compare how participants feel before they start using the device to how they feel after 4 weeks of daily use.\n\nParticipants will:\n\nReceive a Temple Massager System at no cost Complete a 1-week baseline period before using the device Use the device once a day for at least 5 minutes for 4 weeks Answer short daily questions about device use, headaches, and over-the-counter medication use Complete weekly check-in surveys about stress, mood, and sleep Complete longer surveys at the start and end of the study Keep the device after the study ends\n\nThe study runs for 5 weeks per participant and takes place entirely from home through a secure app-based platform. No clinic visits are required.",[450,260,29,259],"Tension Headaches",[452,453,454,455,456,457,458,459,460],"Stress relief","Wellness","Massage device","Temple massage","Facial tension","Relaxation","Women's Health","Decentralized trial","Observational study","2026-06-05",{"date":463,"type":42},"2026-06-10",{"date":463,"type":22},{"date":466,"type":22},"2026-09-30",{"name":468,"class":76},"MOQ Collective, Ltd",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":57,"sex":225,"minAge":477,"maxAge":226,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":496},"100638347","mitigation-of-health-effects-in-pregnant-women-by-reducing-exposure-to-heat-and-air-pollution-100638347","NCT07609433","Mitigation of Health Effects in Pregnant Women by Reducing Exposure to Heat and Air Pollution","Innovative Solutions Across the MEDiterranean for Mitigation of Climate Change-related heaLth rIsks and Enhancing Health systeM Resilience in Pregnant Women","ISMED CLIM PW","Inclusion Criteria:\n\n* Pregnant Women (PW) aged 20 to 35 years\n* being in the 2nd trimester of a singleton pregnancy (15th-27th week of gestation)\n* Living in Catania (Italy) or Limassol (Cyprus) districts\n* Clinically healthy\n* No Gestational diabetes\n* No pre-eclampsia\n* No severe pregnancy complications\n\nExclusion Criteria:\n\n* Currently smoking\n* Presence of any smoking residents in the household\n* Not residing at the household for at least 5 days a week\n* Planning to move from the current home within the next two months\n* No access to Wi-Fi or 4G\u002F5G mobile phone\n* Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, DM2, inflammatory diseases, renal failure, or active cancer)\n* Drugs abuse\n* Alcohol abuse\n* Psychiatric disorders\n* Severe mental disability that interferes with answering questions or following instructions","20 Years",{"count":479,"type":22},102,[25],"The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in pregnant women.\n\nThe main questions it aims to answer are:\n\n* Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)?\n* Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)?\n* Does the intervention (combination of behavioral recommendations for heat mitigation) reduce sleep difficulties experienced by pregnant women, measured using the Pittsburgh Sleep Quality Index?\n\nResearchers will compare measurements between pregnant women carrying out their daily activities in the absence of intervention (control group), those carrying out their daily activities with behavioural recommendations (recommendation intervention group) and those carrying out their daily activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and sleep are different between intervention groups.\n\nParticipants will:\n\n* Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months\n* Have their core temperature measured using an eCelsius medical capsule in three repeated assessments\n* Complete the Pittsburgh Sleep Quality Index questionnaire in three repeated assessments\n* Provide samples of urine and blood biomarkers in three repeated assessments.",[29],[484,485,486,487],"Pregnancy","intervention","Sleep quality","personal ambient temperature exposure","2026-06-03",{"date":461,"type":42},{"date":491,"type":42},"2026-05-01",{"date":493,"type":22},"2027-07-31",{"name":495,"class":49},"University of Cyprus",3,{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":50},"100643704","precision-icu-care-evaluating-an-ai-driven-nursing-decision-support-system-for-delirium-prevention-100643704","NCT07631494","Precision ICU Care: Evaluating an AI-Driven Nursing Decision Support System for Delirium Prevention","Efficacy of an Intelligent Computational Nursing Decision Support System in Precision Critical Care for Delirium Prevention: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 years\n* High risk of developing delirium are defined as PRE-DELIRIC (PREdiction of DELIRium in ICu patients) with a score of ≥40%\n* Sedation assessment form (Richmond Agitation-Sedation). Scale, RASS) is assessed as between +1 and -1\n* Patient is clearly aware and able to communicate with Chinese and Taiwanese customers.\n\nExclusion Criteria:\n\n* Those who have developed delirium before joining the study (assessed by the Intensive Care Delirium Screening Checklist (ICDSC) \\>4 points)\n* Expected to stay in the ICU for less than 24 hours\n* APACHE II score \\> 25 (meaning \\> 50% mortality)\n* Delirium cannot be evaluated, such as those with severe acute brain injury, audio-visual impairment, speech problems, psychotic disorders, aphasia, or in the entire ICU During this period, patient remained comatose.",{"count":505,"type":22},188,[25],"Delirium affects up to 83% of mechanically ventilated patients in the Intensive Care Unit (ICU), often leading to longer hospital stays and long-term memory or cognitive problems. While standard care protocols (such as the ABCDEF bundle) exist, they are often difficult to implement fully due to their complexity and the heavy workload on nursing staff.\n\nTo address these challenges, this study introduces a 'Precision Nursing' approach by integrating Artificial Intelligence (AI) and Virtual Reality (VR). We will implement an AI-driven system to assist nurses in making personalized care decisions more efficiently. Additionally, interactive VR technology will be used to stimulate patients' cognitive function and encourage early mobility. Our goal is to reduce the clinical burden on healthcare providers while significantly improving recovery outcomes for ICU patients.",[318,29],[510,511,512,513,514,515],"Artificial Intelligence","delirium","intensive care unit","Virtual Reality","sleep","machine learning","2026-06-01",{"date":518,"type":42},"2026-06-08",{"date":520,"type":22},"2026-06",{"date":303,"type":22},{"name":523,"class":49},"Taipei Medical University",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":538,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":546},"100640554","mindfulness-meditation-in-hemodialysis-patients-100640554","NCT07620990","Mindfulness Meditation in Hemodialysis Patients","The Effect of Mindfulness Meditation on Sleep, Stress, and Symptoms in Hemodialysis Patients: A Randomized Controlled Trial","MIND-HD","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years\n* Patients receiving hemodialysis treatment for at least 3 months\n* Patients with cognitive functions suitable for the intervention (dementia score ≥21)\n* Patient without hearing, vision or communication problems\n* Patients without a psychiatric diagnosis\n* Patients able to use a smartphone or tablet\n* Patients not participating in another study\n* Patients not using sleep medication or antipsychotic drugs\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 75 years\n* Patients receiving hemodialysis treatment for less than 3 months\n* Patients with cognitive impairment unsuitable for the intervention (dementia score ≤21)\n* Patient with hearing, vision or communication disabilities\n* Patients diagnosed with psychiatric disorders\n* Patients unable to use a smartphone or tablet\n* Patients participating in another study\n* Patients using sleep medication or antipsychotic drugs",{"count":229,"type":22},[25],"This randomised controlled study aims to evaluate the effects of mindfulness meditation on sleep quality, perceived stress and symptoms levels ion hemodialysis patients. Participants in the intervention group will receive a 4 week mindfulness meditation program in addition to routine care. Outcomes will be assessed before and after the intervention using validated measurement tools.",[536,260,29,537],"Hemodialysis","Symptom",[539,536,29,260,537],"Mindfulness Meditation",{"date":154,"type":42},{"date":542,"type":42},"2026-04-15",{"date":131,"type":22},{"name":545,"class":49},"Cyprus Aydin University",4,{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":554,"maxAge":366,"enrollmentInfo":555,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":556,"conditions":557,"keywords":561,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":4},"100639187","impact-of-distress-level-sleep-quality-and-occlusal-trauma-on-periodontal-status-among-bruxers-100639187","NCT07615153","Impact of Distress Level, Sleep Quality and Occlusal Trauma on Periodontal Status Among Bruxers","Impact of Distress Level, Sleep Quality and Occlusal Trauma on Periodontal Status Among Bruxers - a Cross Sectional Study","Inclusion Criteria:\n\nTest Group:\n\n* Adults aged 30-45 years\n* Patients diagnosed with periodontitis according to the 2017 World Workshop classification of periodontal and peri-implant diseases and conditions.\n* Patients who are probable bruxers according to BRUXSCREEN-Q\n* Minimum of 20 natural teeth\n\nControl Group:\n\n* Adults aged 30-45 years\n* Patients diagnosed with periodontitis according to the 2017 World Workshop classification of periodontal and peri-implant diseases and conditions.\n* Patients who are not probable bruxers according to BRUXSCREEN-Q\n* Minimum of 20 natural teeth\n\nExclusion Criteria:\n\n* Systemic conditions affecting periodontium (e.g., diabetes, auto immune disorders)\n* History of drugs having the potential impact on periodontal status like phenytoin, cyclosporin, calcium-channel blockers or antidepressant drugs\n* Patients with pulpal pathology\n* Pregnant or lactating females","30 Years",{"count":283,"type":22},"Increased distress levels and impaired sleep quality are known to exacerbate bruxism by enhancing masticatory muscle activity, leading to excessive and prolonged occlusal forces. These abnormal forces may result in occlusal trauma, which can compromise the adaptive capacity of the periodontal tissues by increasing tooth mobility, widening the periodontal ligament space, and accelerating alveolar bone loss, particularly in the presence of existing periodontal inflammation. Although occlusal trauma alone may not initiate periodontal disease, it can act as an important modifying factor in disease progression. Despite the recognized individual associations of distress, sleep quality, bruxism, and periodontal health, limited evidence exists regarding their combined impact on periodontal status among bruxers. Therefore, evaluating the influence of distress level, sleep quality, and occlusal trauma on periodontal status is essential to better understand disease progression and to facilitate comprehensive, multidisciplinary management strategies for individuals with bruxism.",[558,402,29,559,560],"Periodontitis","Distress Level","Occlusal Trauma",[562,563,63,564,565],"periodontits","bruxism","distress level","occlusal trauma",{"date":488,"type":42},{"date":568,"type":22},"2026-06-22",{"date":570,"type":22},"2027-12-27",{"name":572,"class":49},"Postgraduate Institute of Dental Sciences Rohtak",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":57,"sex":225,"minAge":19,"maxAge":111,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":588,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":50},"100624538","self-acupressure-and-social-jet-lag-in-female-health-sciences-students-100624538","NCT07410936","Self-Acupressure and Social Jet Lag in Female Health Sciences Students","Effects of Self-Acupressure on Social Jet Lag, Sleep Patterns, and Sleep Quality in Female Health Sciences Students: A Sham-Controlled Randomized Trial","Inclusion Criteria:\n\n* Female undergraduate students enrolled in midwifery or medical programs\n* Age 18 to 25 years\n* Regular academic schedule (work\u002Fschool days and free days identifiable)\n* Willingness to participate and provide written informed consent\n* Ability to comply with daily self-acupressure practice for 12 weeks\n* Ability to complete sleep questionnaires and sleep diary\n\nExclusion Criteria:\n\n* Current diagnosis of a sleep disorder requiring medical treatment (e.g., obstructive sleep apnea, narcolepsy)\n* Use of medications known to significantly affect sleep or circadian rhythms (e.g., hypnotics, stimulants)\n* Shift work or night work during the study period\n* Transmeridian travel (≥2 time zones) within the past 4 weeks or planned during the study period\n* Chronic medical or psychiatric condition that may significantly affect sleep\n* Current pregnancy",{"count":581,"type":22},120,[25],"This randomized, sham-controlled trial aims to evaluate the effects of self-administered acupressure on social jet lag, sleep patterns, and sleep quality in female health sciences students. Participants will be randomly assigned to either a self-acupressure intervention group or a sham self-acupressure control group. The intervention will be performed daily for 12 weeks. Outcomes will be assessed at baseline and at the end of the intervention period, with the primary outcome being the change in social jet lag. Secondary outcomes include changes in sleep quality, daytime sleepiness, and participant blinding assessment.",[585,586,29,587],"Social Jet Lag","Sleep Disturbance","Circadian Rhythm Disruption",[589,590,486,591,592,593,594],"Self-acupressure","Social jet lag","Sleep patterns","Circadian rhythm","University students","Sham-controlled trial","2026-05-30",{"date":154,"type":42},{"date":598,"type":42},"2026-04-24",{"date":600,"type":22},"2026-08-15",{"name":602,"class":49},"Nigde Omer Halisdemir University",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":611,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":626,"leadSponsor":628,"locationsCount":4},"100640194","robo-paws-robot-dog-assisted-walking-100640194","NCT07603180","ROBO-PAWS: Robot-Dog-Assisted Walking","ROBO-PAWS: A Pilot Randomized Controlled Trial of Robot-Dog-Assisted Walking to Improve Sleep Quality, Fatigue, and Quality of Life in Pediatric Oncology Patients","ROBO-PAWS","Inclusion Criteria:\n\n* Aged between 2 and 7 years,\n* Diagnosed with cancer and currently receiving active treatment,\n* Pain level not severe enough to interfere with mobilization (FLACC or Wong-Baker FACES score ≤ 4),\n* Diagnosed within the previous 1 month,\n* Medically stable and approved by the physician to participate in light-intensity walking activities,\n* Expected to remain hospitalized for at least 1 month to allow completion of the study protocol,\n* Not scheduled for hematopoietic stem cell transplantation (HSCT) and not currently undergoing HSCT,\n* Hemoglobin level adequate for participation in walking activities (\\>10 g\u002FdL),\n* No significant impairment in consciousness, balance, or motor functions due to heavy analgesic or sedative medication use.\n\nExclusion Criteria:\n\n* Resting SpO₂ \\\u003C94%, requirement for ≥2 L\u002Fmin oxygen support, or recurrent desaturation episodes within the last 24 hours,\n* Heart rate or respiratory rate significantly elevated or irregular for age,\n* Hemodynamic instability,\n* Visual, hearing, or severe cognitive impairment that would prevent interaction with the robotic dog,\n* Increased mobilization risk due to high-dose corticosteroid treatment or medications associated with neurotoxicity,\n* Motor function limitations that would interfere with safe walking,\n* Concurrent severe infection or serious treatment-related complications (e.g., grade 3-4 mucositis or severe neutropenia requiring isolation),\n* Children receiving end-of-life care.","2 Years","7 Years",{"count":168,"type":22},[25],"Childhood cancers affect approximately 400,000 children and adolescents worldwide each year. Although advances in treatment have significantly improved survival rates, children undergoing cancer treatment continue to experience a wide range of treatment-related symptoms and complications. Among these, fatigue and sleep disturbances are particularly common and may persist throughout treatment and survivorship, negatively affecting psychological well-being, cognitive functioning, and overall quality of life. Reduced physical activity during treatment is strongly associated with worsening fatigue, impaired sleep, and decreased quality of life in pediatric oncology patients. However, treatment side effects, prolonged hospitalization, infection risk, and lack of motivating play-based activities often limit children's participation in physical activity during treatment. Recent evidence suggests that physical activity interventions may help reduce fatigue and improve well-being in children with cancer, yet engaging and age-appropriate non-pharmacological interventions remain limited, especially for younger children.\n\nThis pilot randomized controlled trial aims to evaluate the feasibility and potential effects of a robot-dog-assisted walking intervention on sleep quality, fatigue, and quality of life among children aged 2-7 years undergoing cancer treatment.",[29,617,259],"Fatigue",[63,619,620,621],"fatigue","children","cancer","2026-05-19",{"date":624,"type":42},"2026-05-22",{"date":516,"type":22},{"date":627,"type":22},"2027-06-01",{"name":629,"class":49},"Koç University",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":23,"phases":639,"briefSummary":640,"conditions":641,"keywords":666,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":681,"leadSponsor":683,"locationsCount":50},"100637694","assessing-the-effects-of-cool-roofs-on-indoor-environments-and-health-in-tavua-fiji-100637694","NCT07592117","Assessing the Effects of Cool Roofs on Indoor Environments and Health in Tavua, Fiji","A Cluster Randomised Controlled Trial (cRCT) Evaluating the Effects of Cool Roofs on Health, Environmental and Economic Outcomes in Tavua, Fiji","Inclusion Criteria:\n\n* Permanent household resident.\n\nExclusion Criteria:\n\n* Roof damage, inaccessible or instability of roof adversely affecting cool roof coating application.\n* Participant unable to provide written\u002Fverbal informed consent.",{"count":638,"type":22},800,[25],"Ambient air temperatures in Fiji are increasing due to climate change. Solutions are needed to build heat resilience in communities and adapt. Sunlight-reflecting cool roof coatings may passively reduce indoor temperatures and energy use to protect home occupants from extreme heat. Occupants living in poor housing conditions in Fiji are susceptible to increased heat exposure.\n\nHeat exposure can instigate and worsen numerous physical, mental and social health conditions. The worst adverse health effects are experienced in communities that are least able to adapt to heat exposure. By reducing indoor temperatures, cool roof use can promote physical, mental and social wellbeing in household occupants.\n\nThe long-term research goal of the investigators is to identify viable passive housing adaptation technologies with proven health benefits to reduce the burden of heat stress in communities affected by heat in Fiji. To meet this goal, the investigators will conduct a cluster-randomized controlled trial to establish the effects of cool roof use on health, indoor environment and economic outcomes in Tavua, Fiji.",[642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,29,659,660,661,662,663,664,665],"Resting Heart Rate","Blood Glucose Control","Depression","Heat-related Symptoms","Physician Diagnosed Heat-related Illnesses","Food Insecurity","Diet Quality","Health-Related Quality-of-Life","Indoor Thermal Comfort","Coping Ability","Life Satisfaction","Healthcare Provider Utilization","Hospitalization","Systolic Blood Pressure","Diastolic Blood Pressure","Inner Ear Canal Temperature","Dehydration","Cognition","Productivity","Aggression","Indoor Air Temperature","Indoor Relative Humidity","Indoor Heat Index","Household Energy Expenditure",[667,668,669,670,671,644,672,673,674,675,676],"Hot temperature","Humidity","Housing","Heart rate","Cardiovascular","Mental health","Blood glucose","Diabetes","Cool roof","Heat stress","2026-05-11",{"date":679,"type":42},"2026-05-18",{"date":679,"type":22},{"date":682,"type":22},"2027-09-01",{"name":684,"class":49},"Aditi Bunker",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":689,"acronym":4,"eligibilityCriteria":690,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":338,"enrollmentInfo":691,"targetDuration":4,"studyType":23,"phases":693,"briefSummary":695,"conditions":696,"keywords":697,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":701,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":50},"100636806","phase-2-the-effect-of-cbd-on-sleep-quality-following-late-evening-exercise-100636806","NCT07570472","The Effect of CBD on Sleep Quality Following Late Evening Exercise","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Use of highly effective methods of birth control during the entire trial and for up to 4 months after the last dose of CBD; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.\n3. Age between 18-40 years old at the time of signing the Informed Consent Form (ICF)\n4. Recreationally active (between 2-8h\u002Fwk)\n5. Good health status confirmed by a sport medical screening\n6. Body fat percentage below 20% (males) or 25% (females) as estimated by a Dual-energy X-ray absorptiometry (DXA) scan\n7. Good sleep efficiency determined by the Pittsburgh Sleep Quality Index (PSQI, score ≤ 4)\n\nExclusion Criteria:\n\n1. Self-reported sleep disturbances\n2. Habitual smoking (\\> 1 occasion\u002Fmonth)\n3. Any kind of injury\u002Fincapability that is a contra-indication to perform high intensity interval training\n4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n5. Participation in another interventional Trial with an investigational medicinal product (IMP) or device\n6. Use of CBD related products 3 months prior to the start of the experimental trial (including CBD oil, cannabis or other substances containing cannabinoids)\n7. Intake of any medication or nutritional supplement that influences sleep quality 3 months prior to the start of the experimental trial\n8. Shift workers or extreme morning and evening chronotypes (scores between 16-30 or 70-86 on the Morningness-Eveningness Questionnaire (MEQ))",{"count":692,"type":22},20,[694],"PHASE2","The trial is a double-blind, placebo-controlled crossover design. In a randomized order, 20 participants undergo one control and two experimental sessions separated by a 1-week wash out period. During the no exercise\u002Frest session, participants' sleep is monitored via polysomnography following a rest day. During the training sessions participants' sleep is monitored following a high intensity interval training (HIIT) in the late evening (finishing 1h prior to bedtime). During these sessions participants receive 2x 200mg CBD or placebo in a randomized order.",[29],[698,486,699,700],"Cannabidiol","Late evening exercise","Polysomnography","2026-04-30",{"date":703,"type":42},"2026-05-06",{"date":705,"type":42},"2026-03-19",{"date":707,"type":22},"2026-06-07",{"name":709,"class":49},"KU Leuven",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":715,"acronym":4,"eligibilityCriteria":716,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":226,"enrollmentInfo":717,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":719,"conditions":720,"keywords":722,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":727,"lastUpdatePostDateStruct":728,"startDateStruct":730,"completionDateStruct":732,"leadSponsor":733,"locationsCount":50},"100622758","sleep-quality-and-cognitive-functions-in-adults-a-cross-sectional-study-100622758","NCT07387783","Sleep Quality and Cognitive Functions in Adults: A Cross-Sectional Study","The Association Between Sleep Quality and Cognitive Functions in Healthy Young Adults","Inclusion Criteria:\n\n* Between 18 and 35 years.\n* Ability and willingness to provide written informed consent.\n* Sufficient ability to read, understand, and communicate in Turkish, the language in which the assessments are administered.\n* Self-reported good general health, with no active medical or psychiatric conditions that significantly affect daily functioning.\n* Willingness and ability to wear a wearable sleep monitoring device continuously for five consecutive days and to comply with device usage instructions.\n* Ability to attend and complete a single-session cognitive assessment\n\nExclusion Criteria:\n\n* Regular or frequent use of medications known to affect sleep or cognitive function, including sedative-hypnotics, benzodiazepines, antipsychotics, stimulants, opioids, or similar agents.\n* Initiation of, or dose changes in, psychotropic medications within the past four weeks.\n* Being under the influence of alcohol or illicit substances on the day of cognitive testing.\n* Engagement in night shift work or rotating shift schedules within the past one month.\n* Travel across time zones resulting in a time difference of two hours or more within the past two weeks.\n* Uncontrolled high daily intake of caffeine (e.g., \\>400 mg\u002Fday) and unwillingness to reduce consumption during the study period.\n* Color blindness or other color vision deficiencies, due to their potential impact on Stroop Test performance.\n* Dermatological conditions, allergies, or skin lesions at the wrist that prevent wearing the device, or refusal to wear the device as required.\n* Acute illness within the past two weeks, including febrile infections, severe pain, or other acute medical conditions that may temporarily affect sleep or cognitive performance.\n* Pregnancy or early postpartum period.",{"count":718,"type":22},75,"This observational cross-sectional study aims to examine the association between sleep quality and cognitive functions in healthy young adults. Subjective sleep quality will be assessed using the Pittsburgh Sleep Quality Index, and objective sleep parameters will be collected using a wearable device over five consecutive days. Cognitive functions will be evaluated at a single assessment session using standardized neuropsychological tests, including measures of attention, executive functions, and verbal memory. The study seeks to explore relationships between subjective and objective sleep measures and cognitive performance. Findings from this study may contribute to a better understanding of how sleep quality is associated with cognitive functioning in healthy young adults.",[29,721],"Cognitive Functions",[63,723,724,725,726],"Cognitive Function","Young Adults","verbal memory","wearable device","2026-04-27",{"date":729,"type":42},"2026-04-29",{"date":731,"type":42},"2026-01-26",{"date":131,"type":22},{"name":734,"class":49},"Uskudar University"]